医学
嵌合抗原受体
CD19
淋巴瘤
抗原
耐火材料(行星科学)
肿瘤科
化疗
体外
免疫学
癌症研究
内科学
癌症
免疫疗法
生物
天体生物学
生物化学
作者
Eric Tran,Dan L. Longo,Walter John Urba
摘要
More than 7 years have passed since the regression of advanced lymphoma was first reported in a patient who had undergone the infusion of T cells engineered to express a chimeric antigen receptor (CAR) targeting the CD19 antigen expressed on the surface of both normal and malignant B cells.1 Subsequent trials of CD19-targeted CAR T-cell therapy showed a complete response in some patients with relapsed or chemotherapy-refractory hematologic cancers for which there were no effective therapies.2-5 This personalized therapeutic approach entails the removal of peripheral-blood T cells from a patient, followed by in vitro activation, genetic modification, and expansion of . . .
科研通智能强力驱动
Strongly Powered by AbleSci AI